PORTFOLIO
PORTFOLIO COMPANIES
Red Arrow Therapeutics, Inc.
-
- CEO：
- Takuya Miyazaki, Ph.D
-
- Co-founder：
- Horacio Cabral, Ph.D
COMPANY PROFILE
Make Undruggable Treatment Reality by Unlocking Full Potential of Nanomedicine
Red Arrow Therapeutics, Inc. (“Red Arrow”) is an innovative Japanese biotech company that aims to transform the traditional therapeutic into a next-generation therapy for cancer diseases by maximizing the drug potency with minimum toxicity.
COMPANY STORY
Origin
Takuya Miyazaki, Ph.D (CEO) together with Horacio Cabral, Ph.D (Co-founder) launched Red Arrow in 2021 at the University of Tokyo, Japan, who are both experts in polymer-based drug delivery systems.
Strength
Our program, INTERMICIN, pH-sensitive polymeric micelles loading IL-12 release fully active IL-12 upon sensing intertumoral pH, thus increases infiltration and activity of effector immune cells within tumor microenvironment. Moreover, INTERMICIN also overcome the systemic toxicity of IL-12. In the current pre-clinical data, INTERMICIN exhibits strong anti-tumor efficacy in various tumor models both as monotherapy and in combination with immune checkpoint inhibitors.
UTEC’s value add
Ongoing support for team formation, business planning, and financing
-
INTERMICIN reduces off target toxicities with maximal potency
-
INTERMICIN (IL-12/m) Demonstrates Reduced Toxicities as compared to Native IL-12
-
INTERMICIN (IL-12/m) Synergizes with Checkpoint Blockades in Difficult-To-Treat Cold Tumors
